These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 27709352)

  • 21. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer.
    Colomer R; Montero S; Lluch A; Ojeda B; Barnadas A; Casado A; Massutí B; Cortés-Funes H; Lloveras B
    Clin Cancer Res; 2000 Jun; 6(6):2356-62. PubMed ID: 10873087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcome prediction values of soluble human epidermal growth factor receptor-2 extracellular domain in metastatic breast cancer.
    Shao X; Wang X; Xu X; Feng J; Han M; Zhang H; Chen ZH; Wang S; Zang YM; Huang P; Jin H; Wang X
    Int J Clin Exp Pathol; 2014; 7(3):1108-13. PubMed ID: 24696727
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients.
    Darlix A; Lamy PJ; Lopez-Crapez E; Braccini AL; Firmin N; Romieu G; Thezenas S; Jacot W
    BMC Cancer; 2016 Jul; 16():428. PubMed ID: 27387327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma.
    Sandri MT; Johansson H; Colleoni M; Zorzino L; Passerini R; Orlando L; Viale G
    Anticancer Res; 2004; 24(2C):1261-6. PubMed ID: 15154657
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fatty acid synthase activity regulates HER2 extracellular domain shedding into the circulation of HER2-positive metastatic breast cancer patients.
    Vazquez-Martin A; Fernandez-Real JM; Oliveras-Ferraros C; Navarrete JM; Martin-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2009 Dec; 35(6):1369-76. PubMed ID: 19885560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study.
    Colomer R; Llombart-Cussac A; Lloveras B; Ramos M; Mayordomo JI; Fernández R; Tusquets I; Gil M; Barnadas A; Constenla M; Gilabert M; Alba E
    Cancer; 2007 Nov; 110(10):2178-85. PubMed ID: 17926331
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic value of baseline serum HER2 extracellular domain level with a cut-off value of 15 ng/mL in patients with breast cancer: a systematic review and meta-analysis.
    Zhang Z; Li C; Fan H; Xiang Q; Xu L; Liu Q; Zhou S; Xie Q; Chen S; Mu G; Cui Y
    Breast Cancer Res Treat; 2018 Dec; 172(3):513-521. PubMed ID: 30159787
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating Her-2/neu extracellular domain in breast cancer patients-correlation with prognosis and clinicopathological parameters including steroid receptor, Her-2/neu receptor coexpression.
    Barić M; Kulić A; Sirotković-Skerlev M; Dedić Plavetić N; Vidović M; Horvatić-Herceg G; Vrbanec D
    Pathol Oncol Res; 2015 Jul; 21(3):589-95. PubMed ID: 25367073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparative clinical evaluation of the assay of serum extracellular domain of HER2 protein using a chemiluminescent immunoassay method in breast cancer patients with or without HER2 protein expression in immunohistochemistry.
    Mokuyasu S; Suzuki Y; Seto T; Miyachi H; Tokuda Y
    Rinsho Byori; 2012 Jul; 60(7):612-20. PubMed ID: 22973719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Meaningful interpretation of serum HER2 ECD levels requires clear patient clinical background, and serves several functions in the efficient management of breast cancer patients.
    Wang T; Zhou J; Zhang S; Bian L; Hu H; Xu C; Hao X; Liu B; Ye Q; Liu Y; Jiang Z
    Clin Chim Acta; 2016 Jul; 458():23-9. PubMed ID: 27109901
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer.
    Seong MK; Lee JY; Byeon J; Sohn YJ; Seol H; Lee JK; Kim EK; Kim HA; Noh WC
    Breast Cancer Res Treat; 2015 Feb; 150(1):141-8. PubMed ID: 25682076
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel.
    Domingo-Domenech J; Fernandez PL; Filella X; Martinez-Fernandez A; Molina R; Fernandez E; Alcaraz A; Codony J; Gascon P; Mellado B
    Ann Oncol; 2008 Feb; 19(2):269-75. PubMed ID: 17998285
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain.
    Knutson KL; Clynes R; Shreeder B; Yeramian P; Kemp KP; Ballman K; Tenner KS; Erskine CL; Norton N; Northfelt D; Tan W; Calfa C; Pegram M; Mittendorf EA; Perez EA
    Cancer Res; 2016 Jul; 76(13):3702-10. PubMed ID: 27197192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99.
    Eppenberger-Castori S; Klingbiel D; Ruhstaller T; Dietrich D; Rufle DA; Rothgiesser K; Pagani O; Thürlimann B
    BMC Cancer; 2020 Feb; 20(1):114. PubMed ID: 32046665
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer.
    Jensen BV; Johansen JS; Price PA
    Clin Cancer Res; 2003 Oct; 9(12):4423-34. PubMed ID: 14555515
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of plasma HER2 copy number in cell-free DNA of breast cancer patients: a comparison with HER2 extracellular domain protein level in serum.
    Qui S; Takeshita T; Sueta A; Tomiguchi M; Goto-Yamaguchi L; Hidaka K; Suzu I; Yamamoto Y; Iwase H
    Breast Cancer; 2021 May; 28(3):746-754. PubMed ID: 33538993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.
    Hayes DF; Yamauchi H; Broadwater G; Cirrincione CT; Rodrigue SP; Berry DA; Younger J; Panasci LL; Millard F; Duggan DB; Norton L; Henderson IC;
    Clin Cancer Res; 2001 Sep; 7(9):2703-11. PubMed ID: 11555582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies.
    Perrier A; Boelle PY; Chrétien Y; Gligorov J; Lotz JP; Brault D; Comperat E; Lefèvre G; Boissan M
    PLoS One; 2020; 15(1):e0227356. PubMed ID: 31910438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extracellular domain of HER2: a useful marker for the initial workup and follow-up of HER2-positive breast cancer.
    Garoufali A; Kyriakou F; Kountourakis P; Yioti I; Malliou S; Nikaki A; Kardara E; Frangos I; Koumna S; Baziotis N; Scorilas A; Ardavanis A
    J BUON; 2008; 13(3):409-13. PubMed ID: 18979558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum NSE, MMP-9 and HER2 extracellular domain are associated with brain metastases in metastatic breast cancer patients: predictive biomarkers for brain metastases?
    Darlix A; Lamy PJ; Lopez-Crapez E; Braccini AL; Firmin N; Romieu G; Thézenas S; Jacot W
    Int J Cancer; 2016 Nov; 139(10):2299-311. PubMed ID: 27464303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.